tiprankstipranks
Trending News
More News >
Revolution Medicines price target raised to $75 from $70 at Oppenheimer
PremiumThe FlyRevolution Medicines price target raised to $75 from $70 at Oppenheimer
6d ago
Revolution Medicines: Strategic Advancements in NSCLC Treatment Drive Buy Rating
Premium
Ratings
Revolution Medicines: Strategic Advancements in NSCLC Treatment Drive Buy Rating
7d ago
Revolution Medicines’ Promising RAS+ NSCLC Market Position and Drug Efficacy Justify Buy Rating
Premium
Ratings
Revolution Medicines’ Promising RAS+ NSCLC Market Position and Drug Efficacy Justify Buy Rating
7d ago
Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib
PremiumRatingsPositive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib
16d ago
Revolution Medicines shares up 6% after presenting initial RMC-9805 study data
Premium
The Fly
Revolution Medicines shares up 6% after presenting initial RMC-9805 study data
16d ago
Promising Phase 1 Results for Revolution Medicines’ Zoldonrasib in NSCLC Support Buy Rating
Premium
Ratings
Promising Phase 1 Results for Revolution Medicines’ Zoldonrasib in NSCLC Support Buy Rating
17d ago
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs
PremiumCompany AnnouncementsRevolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs
3M ago
Revolution Medicines Reports 2024 Financial Results and Progress
Premium
Company Announcements
Revolution Medicines Reports 2024 Financial Results and Progress
3M ago
Revolution Medicines reports Q4 EPS ($1.12), consensus (96c)
Premium
The Fly
Revolution Medicines reports Q4 EPS ($1.12), consensus (96c)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100